Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | RBP1 | P09455 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4574917 | 0.87 | KMT2A (0.46) | KMT2AMEN1RBP1LMNAALOX5AP | |
| SCHEMBL18014695 | 0.85 | KMT2A (0.45) | KMT2AMEN1RBP1LMNAALOX5AP | |
| SCHEMBL4574604 | 0.81 | KMT2A (0.42) | KMT2AMEN1RBP1LMNAALOX5AP | |
| SCHEMBL23578437 | 0.78 | KMT2A (0.42) | KMT2AMEN1RBP1LMNAALOX5AP | |
| SCHEMBL21116046 | 0.78 | ALOX5AP (0.49) | KMT2AMEN1ALOX5APHSD11B1 | |
| SCHEMBL4746729 | 0.77 | KMT2A (0.40) | KMT2AMEN1RBP1LMNAALOX5AP | |
| SCHEMBL5845934 | 0.76 | ALOX5AP (0.43) | ALOX5APHSD11B1 | |
| SCHEMBL4574617 | 0.75 | KMT2A (0.62) | KMT2AMEN1RBP1LMNAALOX5AP | |
| SCHEMBL23588062 | 0.75 | KMT2A (0.40) | KMT2AMEN1RBP1LMNAALOX5AP | |
| SCHEMBL4574182 | 0.74 | ALOX5AP (0.45) | KMT2AMEN1RBP1LMNAALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052495-B1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2015049616-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | KMT2A 3843/4885MEN1 3008/4885RBP1 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.